Eagle Asset Management Inc. Boosts Holdings in BioLife Solutions, Inc. (NASDAQ:BLFS)

Eagle Asset Management Inc. lifted its stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 2.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 352,897 shares of the medical equipment provider’s stock after buying an additional 10,091 shares during the quarter. Eagle Asset Management Inc.’s holdings in BioLife Solutions were worth $9,221,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Mutual of America Capital Management LLC purchased a new position in shares of BioLife Solutions during the 2nd quarter worth approximately $8,592,000. Vanguard Group Inc. grew its stake in BioLife Solutions by 11.5% in the first quarter. Vanguard Group Inc. now owns 2,868,335 shares of the medical equipment provider’s stock worth $53,208,000 after purchasing an additional 296,727 shares during the period. Raymond James & Associates bought a new position in BioLife Solutions in the second quarter worth $2,876,000. Envestnet Asset Management Inc. lifted its position in BioLife Solutions by 261.5% during the second quarter. Envestnet Asset Management Inc. now owns 127,215 shares of the medical equipment provider’s stock valued at $2,726,000 after buying an additional 92,021 shares during the period. Finally, Fred Alger Management LLC boosted its holdings in shares of BioLife Solutions by 6.0% during the 2nd quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock valued at $33,841,000 after buying an additional 88,840 shares in the last quarter. 93.24% of the stock is owned by institutional investors.

BioLife Solutions Trading Up 2.4 %

Shares of NASDAQ BLFS opened at $26.01 on Friday. The company has a market cap of $1.21 billion, a PE ratio of -24.54 and a beta of 1.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The firm’s 50 day moving average price is $24.00 and its 200-day moving average price is $22.95. BioLife Solutions, Inc. has a 52-week low of $11.91 and a 52-week high of $28.88.

Insider Activity at BioLife Solutions

In related news, CRO Garrie Richardson sold 3,070 shares of BioLife Solutions stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $25.12, for a total value of $77,118.40. Following the completion of the sale, the executive now directly owns 114,773 shares in the company, valued at approximately $2,883,097.76. This trade represents a 2.61 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Aby J. Mathew sold 10,000 shares of the company’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $23.90, for a total transaction of $239,000.00. Following the transaction, the executive vice president now owns 317,716 shares in the company, valued at $7,593,412.40. This represents a 3.05 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 69,644 shares of company stock valued at $1,527,503. 2.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on BLFS. TD Cowen increased their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Craig Hallum raised their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright dropped their price target on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Finally, Northland Securities raised their price objective on BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $27.50.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.